GLP-1 Market
LLY $1288.30 ▲ +0.5% NVO $38.29 ▼ -1.0% PFE $29.45 ▼ -1.2% VKTX $25.36 ▲ +1.9% KLRA $13.42 ▲ +2.2% GPCR $21.48 ▼ -0.3% RHHBY $60.22 ▼ -0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Rifaximin SSD

Company
Bausch Health Americas, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 29, 2026

Find a Clinical Trial Near Me

See recruiting studies for Rifaximin SSD and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06718686

    Rifaximin SSD in Dementia Trial

    Not yet reported, Not yet reported Jasmohan Bajaj 20 participants Est. completion 2027-12-30 1 site Stand-alone
    Other conditions: Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
    View official trial listing →
  • Completed NCT NCT01904409

    Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

    Not yet reported Bausch Health Americas, Inc. 420 participants Est. completion 2015-07 120 sites Stand-alone
    Other conditions: Liver Cirrhosis
    View official trial listing →
  • Terminated NCT NCT01951209

    Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

    Not yet reported David E. Kaplan, MD MSc 13 participants Est. completion 2017-06-12 1 site Stand-alone
    Other conditions: Liver Cirrhosis, Chronic Hepatitis C
    View official trial listing →
  • Completed NCT NCT02124512

    Blood Lipopolysaccharide (LPS) Rifaximin Study

    Not yet reported Philip Kern 12 participants Est. completion 2019-05-31 1 site Stand-alone
    Metabolic syndrome Other conditions: Obese, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT03515044

    Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

    Not yet reported Bausch Health Americas, Inc. 71 participants Est. completion 2020-03-12 34 sites Stand-alone
    Other conditions: Overt Hepatic Encephalopathy
    View official trial listing →
  • Active, not recruiting NCT NCT05071716

    Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

    Not yet reported Bausch Health Americas, Inc. 524 participants Est. completion 2025-09 150 sites Stand-alone
    Other conditions: Hepatic Encephalopathy
    View official trial listing →
  • Completed NCT NCT05297448

    Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

    Not yet reported Bausch Health Americas, Inc. 517 participants Est. completion 2026-02-24 188 sites Stand-alone
    Other conditions: Hepatic Encephalopathy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.